Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application

CW Rinker-Schaeffer, JP O'Keefe, DR Welch… - Clinical cancer …, 2006 - AACR
CW Rinker-Schaeffer, JP O'Keefe, DR Welch, D Theodorescu
Clinical cancer research, 2006AACR
Clinically and experimentally, primary tumor formation and metastasis are distinct processes—
locally growing tumors can progress without the development of metastases. This
observation prompted the hypothesis that the molecular processes regulating tumorigenicity
and metastasis are distinguishable and could be targeted therapeutically. During the
process of transformation and subsequent progression to a malignant phenotype, both
genetic and epigenetic alterations alter a cell's ability to perceive and respond to signals that …
Clinically and experimentally, primary tumor formation and metastasis are distinct processes—locally growing tumors can progress without the development of metastases. This observation prompted the hypothesis that the molecular processes regulating tumorigenicity and metastasis are distinguishable and could be targeted therapeutically. During the process of transformation and subsequent progression to a malignant phenotype, both genetic and epigenetic alterations alter a cell’s ability to perceive and respond to signals that regulate normal tissue homeostasis. A minority of tumorigenic cells accrue the full complement of alterations that enables them to disseminate from the primary tumor, survive insults from the immune system and biophysical forces, and respond to growthpromoting and/or inhibitory signals from the distant tissues and thrive there. Identification of genes and proteins that specifically inhibit the ability of cells to form metastases (eg, metastasis suppressors) is providing new insights into the molecular mechanisms that regulate this complex process. This review will highlight:(a) the functional identification of metastasis suppressors,(b) the signaling cascades and cellular phenotypes which are controlled or modulated by metastasis suppressors, and (c) opportunities for translation and clinical trials that are based on mechanistic studies regarding metastasis suppressors.
AACR